182 related articles for article (PubMed ID: 34376532)
1. Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma.
Nunes R; Sella T; Treuner K; Atkinson JM; Wong J; Zhang Y; Exman P; Dabbs D; Richardson AL; Schnabel CA; Sgroi DC; Oesterreich S; Cimino-Mathews A; Metzger O
Clin Cancer Res; 2021 Oct; 27(20):5688-5696. PubMed ID: 34376532
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer.
Sestak I; Filipits M; Buus R; Rudas M; Balic M; Knauer M; Kronenwett R; Fitzal F; Cuzick J; Gnant M; Greil R; Dowsett M; Dubsky P
Clin Cancer Res; 2020 Sep; 26(17):4682-4687. PubMed ID: 32561662
[TBL] [Abstract][Full Text] [Related]
3. Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
Jerevall PL; Brock J; Palazzo J; Wieczorek T; Misialek M; Guidi AJ; Wu Y; Erlander MG; Zhang Y; Schnabel CA; Goss PE; Horick N; Sgroi DC
Breast Cancer Res Treat; 2019 Jan; 173(2):375-383. PubMed ID: 30350269
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM Trial.
Bartlett JMS; Xu K; Wong J; Pond G; Zhang Y; Spears M; Salunga R; Mallon E; Taylor KJ; Hasenburg A; Markopoulos C; Dirix L; van de Velde CJH; Rea D; Schnabel CA; Treuner K; Bayani J
Clin Cancer Res; 2024 Apr; 30(8):1509-1517. PubMed ID: 38345755
[TBL] [Abstract][Full Text] [Related]
5. A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR
Zhang Y; Schroeder BE; Jerevall PL; Ly A; Nolan H; Schnabel CA; Sgroi DC
Clin Cancer Res; 2017 Dec; 23(23):7217-7224. PubMed ID: 28939745
[No Abstract] [Full Text] [Related]
6. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
[TBL] [Abstract][Full Text] [Related]
7. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
[TBL] [Abstract][Full Text] [Related]
8. Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Sestak I; Zhang Y; Schroeder BE; Schnabel CA; Dowsett M; Cuzick J; Sgroi D
Clin Cancer Res; 2016 Oct; 22(20):5043-5048. PubMed ID: 27252417
[TBL] [Abstract][Full Text] [Related]
9. Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
Jankowitz RC; Cooper K; Erlander MG; Ma XJ; Kesty NC; Li H; Chivukula M; Brufsky A
Breast Cancer Res; 2011 Oct; 13(5):R98. PubMed ID: 21999244
[TBL] [Abstract][Full Text] [Related]
10. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients.
Korhonen T; Kuukasjärvi T; Huhtala H; Alarmo EL; Holli K; Kallioniemi A; Pylkkänen L
Breast; 2013 Dec; 22(6):1119-24. PubMed ID: 23863867
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Sgroi DC; Chapman JA; Badovinac-Crnjevic T; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Shepherd LE; Goss PE; Pollak M
Breast Cancer Res; 2016 Jan; 18(1):1. PubMed ID: 26728744
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Treatment Outcome Between Invasive Lobular and Ductal Carcinomas in Patients Receiving Partial Breast Irradiation With Intraoperative Electrons.
Leonardi MC; Maisonneuve P; Mastropasqua MG; Cattani F; Fanetti G; Morra A; Lazzari R; Bazzani F; Caputo M; Rotmensz N; Gerardi MA; Ricotti R; Enrica Galimberti V; Veronesi P; Dicuonzo S; Viale G; Jereczek-Fossa BA; Orecchia R
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):173-181. PubMed ID: 28816144
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.
Zhang Y; Schnabel CA; Schroeder BE; Jerevall PL; Jankowitz RC; Fornander T; Stål O; Brufsky AM; Sgroi D; Erlander MG
Clin Cancer Res; 2013 Aug; 19(15):4196-205. PubMed ID: 23757354
[TBL] [Abstract][Full Text] [Related]
16. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
[TBL] [Abstract][Full Text] [Related]
17. Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence.
Conforti F; Pala L; Pagan E; Viale G; Bagnardi V; Peruzzotti G; De Pas T; Bianco N; Graffeo R; Rocco EG; Vingiani A; Gelber RD; Coates AS; Colleoni M; Goldhirsch A
Breast Cancer Res; 2019 Dec; 21(1):153. PubMed ID: 31888717
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
19. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.
Jung SY; Jeong J; Shin SH; Kwon Y; Kim EA; Ko KL; Shin KH; Lee KS; Park IH; Lee S; Kim SW; Kang HS; Ro J
BMC Cancer; 2010 Dec; 10():664. PubMed ID: 21126378
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
